Medtronic completes acquisition of CathWorks

Apr 20, 2026

Medtronic has completed its acquisition of Israeli imaging analysis software developer CathWorks for $585 million with potential additional earn-out payments.

Under terms of the deal, Medtronic acquires CathWorks' FFRangio System, an AI-based platform that provides physiological assessment of the coronary tree from drug-free, wire-free coronary CT angiography (CCTA) exams, the company said. The system differs from traditional wire-based fractional flow reserve (FFR) assessment, which requires pressure wires, pharmacologic hyperemia, and measurements limited to a single transducer location.

The acquisition follows a 2022 strategic partnership and co-promotion agreement for the FFRangio System in the U.S., Europe, and Japan, and expands Medtronic's interventional cardiology portfolio, according to the firm.

$Acute radiation-induced pneumonitis after SBRT (65 Gy, four fractions) in a 53-year-old woman with leiomyosarcoma of the uterus with a left lower lobe metastasis manifesting as a small nodule (not shown). (A) Axial dosimetric reconstruction of a CT image obtained for SBRT planning shows the metastasis receiving the maximal isodose (6500 cGy). (B) Axial CT image obtained 12 months after completion of RT shows focal ground-glass and consolidative opacities confined to the treatment plan (arrow). Note that acute lung injury with SBRT typically manifests later than with conventional RT (i.e., >12 weeks after completion of therapy), and in 25% of patients, the first CT manifestations occur more than one year after completion of RT.$